Ivermectin for preventing and treating COVID-19
Maria Popp, Stefanie Reis, Selina Schießer, Renate Ilona Hausinger, Miriam Stegemann, Maria-Inti Metzendorf, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel
Cochrane Database of Systematic Reviews, doi:10.1002/14651858.cd015017.pub3
Analysis 1.1. Comparison 1: Ivermectin for treating COVID-19 in inpatient settings with moderate to severe disease, Outcome Analysis 2.12. Comparison 2: Ivermectin for treating COVID-19 in outpatient settings with asymptomatic or mild disease, Outcome
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Study characteristics
Methods • Trial design: triple-blind RCT with 3 parallel arms, the 2 intervention arms were pooled for this review • Type of publication: pre-proof journal publication • Severity of condition according to study definition: mild disease, defined as not requiring hospitalization or oxygen supplementation • Severity of condition according to WHO scale: 1 to 3 • Time from symptom onset to enrolment (median): overall 4 (IQR 3 to 5.5) days • Comorbidities: any pre-existing condition, obesity, diabetes, cardiovascular disease, respiratory disease • Virus detection performed at baseline (test-positive at baseline): RT-PCR (100%) • Vaccination status: overall 91 (98%) participants without any vaccination • Inclusion criteria: age ≥ 18 years; positivity for SARS-CoV-2 (nasopharyngeal swabs) by RT-PCR; consent to participating in the study and to the processing of personal data; COVID-19 Severity Score < 3; participant able to take oral drugs Cochrane Database of Systematic Reviews • Exclusion criteria: pregnant or lactating women (pregnancy test not required, if doubt person is excluded); people with known central nervous system disease; lack of (or inability to provide) informed consent; receiving dialysis; any severe medical condition with a prognosis of < 6 months; receiving warfarin treatment; receiving antiviral treatment; receiving..
References
Blankenfeld, Kaduszkiewicz, Kochen, Pömsl, Scherer et al., Interleukin-6 blocking agents for treating COVID-19: a living systematic review,
doi:10.1002/14651858.CD013881
Deeks, Higgins, Altman, Chapter 10: Analysing data and undertaking meta-analyses
Garegnani, Madrid, Meza, Misleading clinical evidence and systematic reviews on ivermectin for COVID-19, BMJ Evidence Based Medicine
German Awmf Guideline 2021a Kluge, Janssens, Welte, Weber-Carstens, Schälte et al., S3-Guideline -recommendations on Inpatient Treatment of Patients With COVID-19
German Awmf Guideline, None
Goetz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of e icient nuclear vRNP import, Scientific Reports,
doi:10.1038/srep23138
González-Canga, None
González-Canga, Sahagún-Prieto, Diez-Liébana, Fernández-Martínez, Vega et al., The pharmacokinetics and interactions of ivermectin in humans, Journal of the American Association of Pharmaceutical Scientists,
doi:10.1208/s12248-007-9000-9
Herrmann, Adam, Notz, Helmer, Sonntagbauer et al., COVID-19 induced acute respiratory distress syndrome -a multicenter observational study
Higgins, Lasserson, Chandler, Tovey, Thomas et al., Retraction: Expression of Concern: "Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection, Open Forum Infectious Diseases,
doi:10.1093/ofid/ofab358
Izcovich, Peiris, Ragusa, Tortosa, Rada et al., Bias as a source of inconsistency in ivermectin trials for COVID-19: a systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results, Journal of Clinical Epidemiology,
doi:10.1016/j.jclinepi.2021.12.018
Karagiannidis, Mostert, Hentschker, Voshaar, Malzahn et al., Case characteristics, resource use, and outcomes of 10,021 patients with COVID-19 admitted to 920 German hospitals: an observational study, Lancet Respiratory Medicine,
doi:10.1016/S2213-2600(20)30316-7
Kobayashi, Jung, Linton, Kinoshita, Hayashi et al., Communicating the risk of death from novel coronavirus disease (COVID-19), Journal of Clinical Medicine,
doi:10.3390/jcm9020580
Kory, Meduri, Varon, Iglesias, Marik, Review of the emerging evidence demonstrating the e icacy of ivermectin in the prophylaxis and treatment of COVID-19, American Journal of Therapeutics,
doi:10.1097/MJT.0000000000001377
Kreuzberger, Hirsch, Chai, Tomlinson, Khosravi et al., SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19, Cochrane Database of Systematic Reviews,
doi:10.1002/14651858.CD013825.pub2
Lefebvre, Glanville, Briscoe, Littlewood, Marshall et al., Chapter 4: Searching for and selecting studies
Mikolajewska, Fischer, Piechotta, Mueller, Metzendorf et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Cochrane Database of Systematic Reviews,
doi:10.1002/14651858
Oran, Topol, The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review, Annals of Internal Medicine,
doi:10.7326/M20-6976
Panahi, Poursaleh, Goldust, The e icacy of topical and oral ivermectin in the treatment of human scabies, Annals of Parasitology
Popp, Kranke, Meybohm, Metzendorf, Skoetz et al., Evidence on the e icacy of ivermectin for COVID-19: another story of apples and oranges, BMJ Evidence Based Medicine,
doi:10.1136/bmjebm-2021-111791
Ritchie, Mathieu, Rodés-Guirao, Appel, Giattino et al., Coronavirus pandemic (COVID-19)
Rodríguez-Mega E ; Rothrock ; Rothrock, Weber, Giordano, Barneck, Meta-Analyses do not establish improved mortality with ivermectin use in COVID-19, American Journal of Therapeutics,
doi:10.1038/d41586-020-02958-2
Rodríguez-Mega, None
Schünemann, Higgins, Vist, Glasziou, Akl et al., Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence
Singh, Ryan, Kredo, Chaplin, Fletcher et al., Vitamin D supplementation References to other published versions of this review Popp, Cochrane Database of Systematic Reviews,
doi:10.1002/14651858